# MNTL (Tema Neuroscience and Mental Health ETF)

Tema · Thematic ETFs · data as of Sep 11, 2026

MNTL has not filed its holdings yet, so there is nothing to look through.

## Key facts

- MNTL, total return, since launch: 0.0%, as of Sep 11, 2026.
- MNTL, expense ratio: 0.75% (485BPOS XBRL, Jun 26, 2025).

## MNTL over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | 0.0% | +3.3% | −3.3 pts | +0.8 pts |
| 6 months | 0.0% | +15.4% | −15.4 pts | −20.0 pts |
| Since launch | 0.0% | +11.3% | −11.3 pts | −17.5 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Therapeutics and medical devices | ETFIQ, editorial |
| Launched | Feb 6, 2026 | ETFIQ |
| Below its all-time high | 0.0% | ETFIQ |
| Expense ratio | 0.75% | 485BPOS XBRL, Jun 26, 2025 |

## Questions

### Has MNTL beaten the S&P 500?

Over the year to Sep 11, 2026 MNTL returned 0.0% with distributions reinvested, against +11.3% for the S&P 500, so it finished behind the index by 11.3 points.

### What does MNTL cost?

The prospectus expense ratio is 0.75% a year.


## Cite this page

ETFIQ, MNTL, data as of Sep 11, 2026. https://etfiq.com/funds/MNTL
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/MNTL  ·  JSON: https://etfiq.com/funds/MNTL.json